Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19

https://www.journalofinfection.com/article/S0163-4453(20)30188-2/pdf

In the present study, the authors anayzed  the efficacy and safety of lopinavir/ritonavir and arbidol monotherapy in patients with COVID-19. On day 14 after the admission, no viral load was detected in the arbidol group, but the viral load was found in 44.1% of the patients treated with lopinavir/ritonavir. Furthermore, no apparent side effects were found in both groups. Data from the study indicates that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19

Tags: ,